
RenehaVis™ 1 x 1.4 ml
Kurzbeschreibung:
Brief description:
Breve descripción:
Artikel: RenehaVis™
Hersteller: LSP Bio Ltd.
Konzentration: 0.7ml LMW Hyaluronsäure 22mg/ml & 0.7ml HMW Hyaluronsäure 10mg/ml
Packungsinhalt: 1 x 1.4 ml Fertigspritze
Article: RenehaVis™
Manufacturer: LSP Bio Ltd.
Concentration: 0.7ml LMW hyaluronic acid 22mg/ml & 0.7ml HMW hyaluronic acid 10mg/ml
Package content: 1 x 1.4ml
Artículo: RenehaVis™
Fabricante: LSP Bio Ltd.
Concentración: 0,7 ml de ácido hialurónico LMW 22mg/ml y 0,7 ml de ácido hialurónico HMW 10mg/ml
Contenido del paquete: 1 x 1,4 ml
Article: RenehaVis™
Fabricant: LSP Bio Ltd.
Concentration: 0.7ml LMW acide hyaluronique 22mg/ml & 0.7ml HMW acide hyaluronique 10mg/ml
Contenu de l'emballage: 1 x 1.4 ml
RenehaVis™ 1 x 1.4 ml Im Warenkorb
XDas passt dazu
RenehaVis™ | Osteoarthritis therapy
RenehaVis™ is designed to relieve pain and stiffness associated with degenerative changes in the knee joint. RenehaVis™ is a unique dual-chamber injection that contains two different hyaluronic acids at two different concentrations in one syringe.
The hyaluronic acid covers the surface of the cartilage and fills the spaces in the undulating structure of the surface. The lubricating and shock-absorbing effect of the RenehaVis™ dual-chamber syringe relieves pain and improves joint mobility.
RenehaVis™ consists of two sterile, transparent solutions of sodium hyaluronate dissolved in phosphate-buffered saline in a double-chamber syringe.
These 3 properties make RenehaVis™ unique:
- The first chamber contains a solution consisting of 2.2% low molecular weight hyaluronic acid.
- The second chamber contains a solution of 1.0% high molecular weight hyaluronic acid.
- The effectiveness of the dual-chamber syringe is based on its biocompatibility and physicochemical properties: "RenehaVis™" replenishes the natural sodium hyaluronate in the synovium (synovial fluid), which decreases due to changes in the joint.